- Trials with a EudraCT protocol (3)
 - Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
 
		
	   		
	   		    
                    
                   	
                   	    3 result(s) found for: Aerobics.
                    
                
			
   			
		
		Displaying page 1 of 1.
	
	
| EudraCT Number: 2017-004259-22 | Sponsor Protocol Number: ISIS766720-CS2 | Start Date*: 2018-06-05 | |||||||||||
| Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered... | |||||||||||||
| Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma. | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) PL (Completed) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-000675-20 | Sponsor Protocol Number: ISIS766720-CS5 | Start Date*: 2020-11-04 | |||||||||||
| Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
| Full Title: An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherap... | |||||||||||||
| Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma. | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) LT (Completed) PL (Completed) LV (Prematurely Ended) IT (Completed) RO (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-001081-38 | Sponsor Protocol Number: ARCT-810-03 | Start Date*: 2021-12-23 | |||||||||||
| Sponsor Name:Arcturus Therapeutics, Inc. | |||||||||||||
| Full Title: Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult ... | |||||||||||||
| Medical condition: Ornithine transcarbamylase deficiency | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) ES (Completed) FR (Completed) SE (Completed) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
    	Query did not match any studies.